Relationship between Microsatellite Status and Other Prognostic Factors in Patients with Colon Cancer

Main Article Content

Ogün Erşen
Serdar Çulcu
Ferit Aydın
Ümit Mercan
Cemil Yüksel
Ali Ekrem Ünal

Abstract

It is reported that 0.5-13 % of all colorectal cancers are hereditary. Many mutations that cause genomic instability have been described lately in this cancers; the most famous one is yet microsatellite instability pathway. Investigating the presence of these mutations is important in tailoring patients' treatment and predicting prognosis.

Aims: We evaluated the association between micro satellite status and other pathologic prognostic factors like grade, tumor size, lymph node metastasis, lymphovascular invasion and perineural invasion in patients who underwent curative colon resection for colorectal cancers (CRC) in our clinic in the past five years.

Study Design: A total of 205 sequential patients who were older than 18 and had curative colon resection for CRC in Ankara University Surgical Oncology Unit and been tested for microsatellite instability (MSI) were analyzed on behalf of the facultys’ database.

Methodology: Pathology results had been determined and tumor localizations, lymph node metastasis status, grade, lymphovascular and perineural invasion status were evaluated. Information about MSI status and defected genes were obtained from detailed pathology reports. Patients were divided into two groups as MSI and MSS.

Results: No significant difference was found between two the groups in the context of microsatellite instability status. Lymphovascular invasion had been seen higher in high frequency microsatellite instability (MSH-H) compared to low frequency microsatellite instability (MSH-L)  group (76.4% vs 53.1%, P =.02). There was no statistical difference in perineural invasion between the two groups (P = 0.102). Signet ring cell status between the groups we found a higher rate of signet ring cells and consequently a higher grade in MSH-H group (17.6% vs 10.6%, P = 0.042).

Conclusion: In conclusion, although many important points have been identified in our study, more studies are needed to compare the evaluation of MSI in colon cancer with other prognostic factors and to investigate its effect on the course of the disease.

Keywords:
Colon cancer, micro satellite status, prognosis, mutations.

Article Details

How to Cite
Erşen, O., Çulcu, S., Aydın, F., Mercan, Ümit, Yüksel, C., & Ünal, A. E. (2020). Relationship between Microsatellite Status and Other Prognostic Factors in Patients with Colon Cancer. Journal of Cancer and Tumor International, 10(3), 18-23. https://doi.org/10.9734/jcti/2020/v10i330129
Section
Original Research Article

References

Lynch HT, Smyrk T, Lynch J. Genetics and cancer of the gastrointestinal tract. In: H. J. Wanebo (ed.). Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach, Philadelphia: Lippincott-Raven Publishers. 1997;59-86.

Pena-Diaz J, Rasmussen LJ. Approaches to diagnose DNA mismatch repair gene defects in cancer. DNA repair. 2016;38:147-154.

Gupta R, Sinha S, Paul RN. The impact of microsatellite stability status in colorectal cancer. Current problems in cancer. 2018;42(6):548-559.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–3226.

Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531–6541.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27:1814–1821.

Vranic S. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. Bosnian Journal of Basic Medical Sciences. 2017;17(3), 274-275.

O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C et al. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PloSone. 2017;12(12):e0189848.

Mejri N, Dridi M, El Benna H, Labidi S, Daoud N, Boussen H. Prognostic value of tumor size in stage II and III colorectal cancer in Tunisian population. Colorectal Cancer. 2017;6(4):113-119.

Haydon AMM, Jass JR. Emerging pathways in colorectal-cancer development.The Lancet Oncology. 2002;3:83-88

Lawes DA, Gupta SS, Boulos PB. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. EJSO. 2003;29:201- 212.

Rass JR. HNPCC and Sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Familial Cancer. 2004;3:93-100.

Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine. 2018;97(9).

Jung SH, Kim SH, Kim JH. Prognostic impact of microsatellite instability in colorectal cancer presenting with mucinous, signet-ring, and poorly differentiated cells. Annals of coloproctology. 2016;32(2):58.

Emterling A, Wallin A, Arbman G, Sun XF. Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Ann Oncol. 2004;15:242–6.

Ward R, Meagher A, Tomlinson I, O'connor T, Norrie M, Wu R. et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut. 2001;48: 821–9.

Buckowitz A, Knaebel HP, Benner A, Bläker H, Gebert J, Kienle P. et al. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low requency of distant metastases. Br J Cancer. 2005;92:1746–53.